发明名称 PHARMACEUTICAL COMPOUNDS
摘要 Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof, wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; R1a is an optionally substituted aryl or heteroaryl group; R1b is hydrogen or a group R1a; X is an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 are heteroatoms selected from O, N and S; and A, E, R2, R3, R4, Q1 and Q2 are as defined in the claims; provided that when E is aryl or heteroaryl, then Q2 is other than a bond; and further provided that the moiety (a) is other than a group (BG1) or (BG2); wherein (BG1) and (BG2) are each optionally substituted; T is N or CRZ; J1-J2 is selected from N-C(RZ), (RZ)C-N, (RZ)N-C(O), (RZ)2C-C(O), N-N and (RZ)C-C(R6); J4-J3 is a group N-C(RZ) or a group (RZ)N-CO; and RZ is hydrogen or a substituent. The compounds of the formula (I) have PKA and PKB kinase inhibiting activity and are useful in the treatment of cancers.
申请公布号 US2009124610(A1) 申请公布日期 2009.05.14
申请号 US20070298384 申请日期 2007.04.25
申请人 SAXTY GORDON;VERDONK MARINUS LEENDERT;CALDWELL JOHN;COLLINS IAN;CHEUNG KWAI-MING;DA FONSECA MCHARDY TATIANA FARIA 发明人 SAXTY GORDON;VERDONK MARINUS LEENDERT;CALDWELL JOHN;COLLINS IAN;CHEUNG KWAI-MING;DA FONSECA MCHARDY TATIANA FARIA
分类号 A61K31/5383;A61K31/437;A61K31/44;A61K31/445;A61K31/496;A61K31/519;C07D211/06;C07D211/56;C07D401/14;C07D409/14;C07D413/14;C07D495/04 主分类号 A61K31/5383
代理机构 代理人
主权项
地址